^
Association details:
| Biomarker: | BRCA wild-type |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + adavosertib (AZD1775) (WEE1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer
Published date:
08/15/2023
Excerpt:
Our findings demonstrate that combined treatment with olaparib (PARPi) and advertosertib (AZD1775; WEE1i) increased STING-mediated proinflammatory cytokine production in BRCA1/2 wild-type TNBC models. Anti-tumour efficacy and immune responses were more prominent in tumours with higher levels of baseline T cell infiltrate. Our results have also identified baseline TIL levels as a potential predictive biomarker of PARPi, WEE1i and immunotherapy in BRCA1/2 wild-type TNBC....These findings suggest that AZD1775 can sensitise BRCA1/2 wild-type TNBC cell lines to olaparib monotherapy.
DOI:
https://doi.org/10.1038/s41523-023-00568-5
